Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 15-patient Phase I study, PDLI said that Nuvion gave no toxicities or allergic or inflammatory
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury